Biomarin R&D day: massive patient-to-patient variability for Hemo A | SGMO Message Board Posts

Sangamo Therapeutics, Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  136575 of 149003  at  11/17/2019 5:12:23 PM  by

civic08801


 In response to msg 136573 by  spaddy
view thread

Re: Biomarin R&D day: massive patient-to-patient variability for Hemo A

It will be interesting to see what the FDA Advisory Board will recommend,which I guess will be after ASH.

I am sure Biomarin will Lobby the FDA if the Advisory Board Rejects their submission. WHAT IS YOUR ASSESSMENT RE WHAT do you think will be the consensus of the doctors re their l recommendations to their patients ?



     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 1     Views: 271
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
136580 Re: Biomarin R&D day: massive patient-to-patient variability for Hemo A spaddy 5 11/17/2019 9:49:43 PM






Financial Market Data provided by
.


Loading...